Status | Study |
Recruiting |
Study Name: Assessment of Immunogenicity of Zostavax® in Patients With Antibody Deficiency 60 Years of Age and Older Condition: Common Variable Immune Deficiency Specific Antibody Deficiency Date: 2016-10-03 Interventions: Biological: Zostavax® Zostavax® immunization |
Not yet recruiting |
Study Name: Clinical and Virological Efficacy of Pegylated Interferon Alpha in the Treatment of Rhinovirus Infection in Patients With Primary Hypogammaglobulinemia: Randomized Controlled Trial Condition: Rhinovirus Infection Date: 2016-01-13 Interventions: Drug: pegylated interferon alfa 2 Other: P |
Enrolling by invitation |
Study Name: Personalized Immunotherapeutic for Antibiotic-resistant Infection Condition: Infection Immune Deficiency Hypogammaglobulinemia Date: 2015-07-09 Interventions: Biological: anti-mycoplasma hominis antibodies provision of customized anti-mycoplasma hominis antibodie |
Recruiting |
Study Name: Mutation of the BTK Gene and Genotype-phenotype Correlation of Chinese Patients With X-Linked Agammaglobulinemia Condition: Agammaglobulinemia, BTK Date: 2014-08-29 |
Completed |
Study Name: Post-bypass Prophylactic IVIG in Infants and Neonates Condition: Hypogammaglobulinemia Congenital Heart Disease Date: 2014-01-14 Interventions: Drug: IVIG Those randomized to |
Completed |
Study Name: Treatment of SCID Due to ADA Deficiency With Autologous Transplantation of Cord Blood or Hematopoietic CD 34+ Cells After Addition of a Normal Human ADA cDNA by the EFS-ADA Lentiviral Vector Condition: Adenosine Deaminase Deficiency ADA-SCID Date: 2013-12-20 Interventions: Genetic: Lentiviral Gene Transfer |
Recruiting |
Study Name: Participation in a Research Registry for Immune Disorders Condition: ADA-SCID Adenosine Deaminase Deficiency Wiskott- Aldrich S Date: 2013-09-25 |
Completed |
Study Name: Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases Condition: Primary Immune Deficiency Disorders Common Variable Immunodeficiency Date: 2013-09-13 Interventions: Biological: Gammaplex (5%) Biological: Gam |
Terminated |
Study Name: Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL) Condition: Hematologic Disorder Date: 2013-08-13 Interventions: Drug: Lenalidomide |
Active, not recruiting |
Study Name: Pharmacokinetics (PK) and Safety of Subgam-VF in Primary Immunodeficiency Diseases Condition: Primary Immune Deficiency Disorders Common Variable Immunodeficiency Date: 2013-06-14 Interventions: Biological: Subgam Subgam-VF dose will be given as 1.37 of the established IGIV dose (expressed in mg/kg |